{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihundlxrv47mbr6vouqai2kcmzqzksy2em3rklt6jx4c6dlrreof4",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mmcoplkwxnd2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidpkg7zn3vkr2lspkg4chpwgys467qoygcydy5rjpm6tbxozeut6m"
    },
    "mimeType": "image/jpeg",
    "size": 1528917
  },
  "path": "/news/2026-05-keratin-resistance-pancreatic-cancer.html",
  "publishedAt": "2026-05-20T14:40:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A national team of cancer researchers led by Drs. Kenneth Shroyer and Natalia Marchenko at Stony Brook Medicine, and Dr. Luisa Escobar-Hoyos of Yale School of Medicine, investigated the role of Keratin 17 (K17) in the most common form of pancreatic cancer. They discovered that the protein is a key driver for chemoresistance to gemcitabine, an agent that is often used to treat a wide range of cancers, including advanced tumors of the pancreas, lungs and breast. Their findings highlight K17 as a potential target for the development of novel treatments to address the most aggressive forms of cancer.",
  "title": "Keratin 17 drives resistance in pancreatic cancer, study finds"
}